Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes

Fouqueray, Pascale; Leverve, Xavier; Fontaine, Eric; Baquie, Mathurin; Wollheim, Claes; Lebovitz, Harold; Bozec, Sophie

doi:10.4172/2155-6156.1000126

Scientific article

English

Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes

ContributorsFouqueray, Pascale; Leverve, Xavier; Fontaine, Eric; Baquie, Mathurin; Wollheim, Claes; Lebovitz, Harold; Bozec, Sophie

Published inJournal of diabetes & metabolism, vol. 2, no. 4

Publication date2011

Affiliation

Faculté de médecine / Section de médecine fondamentale / Département de pathologie et immunologie

Citation (ISO format)

FOUQUERAY, Pascale et al. Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes. In: Journal of diabetes & metabolism, 2011, vol. 2, n° 4. doi: 10.4172/2155-6156.1000126

Article (Published version)

Identifiers

PID : unige:47301
DOI : 10.4172/2155-6156.1000126

Commercial URLhttp://www.omicsonline.org/2155-6156/2155-6156-2-126.digital/2155-6156-2-126.html

ISSN of the journal2155-6156

811views

1downloads

Creation02/26/2015 3:59:00 PM

First validation02/26/2015 3:59:00 PM

Update time03/14/2023 10:55:56 PM

Status update03/14/2023 10:55:56 PM

Last indexation08/29/2023 3:01:05 PM

Archive ouverte UNIGE

Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes

Technical informations